A：The full year 2026 adjusted earnings per share guidance was revised to a range of $7.30 to $7.50, up from the previous range of $7.00 to $7.20.

A：Cvs Health is focused on driving change across the healthcare ecosystem, strengthening relationships with all stakeholders to address key priorities, and improving health care. They are collaborating with CMS regulators and legislators to discuss issues, develop constructive solutions, and implement a consumer-centric approach. They're also working to ensure value-based care and addressing the detrimental impact of proposed risk model changes.

A：The core principles of the company's guidance philosophy are credible targets, disciplined execution, and clear opportunities for outperformance.

A：The challenges within the Medicare Advantage Program include final rate notices that do not sufficiently offset underlying medical cost trends, which remain above historical levels and have pressurized the industry, including Cvs Health's own Medicare business, resulting in an adjusted operating loss.

A：Cvs Health is committed to ensuring every American has access to certain insulin products for $25 per month. They're converting over 90% of eligible patients to this pricing model, delivering frictionless experiences for providers and patients, with similar conversion rates expected for the majority of customers.

A：The company's focus regarding prior authorization processes is on reducing unnecessary friction for providers and patients. They aim to approve most eligible prior authorizations within 24 hours, with over 80% being approved in real-time. They've integrated medical and pharmacy decisions and introduced bundling solutions for certain conditions. The company is also leading the way by standardizing prior authorization submissions and has rallied with industry peers to commit to standardized services for the most common prior authorizations.

A：The vision for Health 100 is to create an open consumer engagement platform with the consumer at the center. It is an AI-native, state-of-the-art technology and service platform that will allow payers, health systems, and providers to integrate their services with the Health 100 app. This app is designed to be the consumer's front door to a fully integrated healthcare experience, regardless of the brand of their benefit card or pharmacy.

A：The company believes technology and AI are essential for healthcare companies because they see an immense opportunity for technology to drive systemic change across the healthcare industry. They are embedding technology in everything they do to ensure they are best in class in each of their businesses and are developing tech-forward solutions like Health 100 to power the future of best-in-class healthcare companies.

A：AI in CBS Health is being used to improve consumer experiences, engagement, and outcomes by helping members find the right providers, navigating the system more effectively, empowering pharmacists and clinicians with insights, accelerating go to market strategies, and driving innovation across the enterprise.

A：The priorities for the company include disciplined execution, partnership with stakeholders across the healthcare system, and a continued focus on innovating to improve affordability, access, and simplifying the healthcare experience, one person, one family, and one community at a time.

A：The company's first quarter results showed revenue of over $100 billion, an increase of over 6% from the prior year quarter. Adjusted operating income increased over 12%, and adjusted EPS grew by a meaningful increase of over 14%. The company generated cash flow from operations of approximately $4.2 billion. For the remainder of the year, the company has revised its financial outlook, expecting adjusted EPS to be in a range of $7.30 to $7.50, with total revenues of at least $405 billion, and full year cash flow from operations at least $9.5 billion.

A：The adjusted operating income in the quarter was approximately $3 billion, and the medical benefit ratio was 84.6%. This reflects a substantial improvement from the prior year quarter as the company continued to execute on its margin recovery plans at Aetna.

A：The health services segment generated revenues of over $40 billion, an increase of more than 5% over the prior year. Adjusted operating income was approximately $1.5 billion, a decrease of approximately 7% from the prior year quarter. Results were affected by continued pharmacy client price improvements but were partially offset by improved purchasing economics and pharmacy drug mix. The segment's performance also included the early recognition of value previously expected to occur in the second quarter, modestly exceeding expectations.

A：The pharmacy and consumer wellness segment generated revenues of nearly $32 billion, which remained consistent with the prior year quarter. Adjusted operating income decreased approximately 9% from the prior year to about $1.2 billion. The segment saw increases primarily driven by pharmacy drug mix, increased prescription volumes, and brand inflation, but these were offset by the impact of regulatory price reductions on select drugs and the impact of generic drug introductions and pharmacy reimbursement pressure.

A：In the first quarter, the company generated cash flows from operations of approximately $4.2 billion and returned nearly $850 million to shareholders through a quarterly dividend. It ended the quarter with approximately $2.2 billion of cash at the parent and unrestricted subsidiaries. The leverage ratio at the end of the first quarter improved to 3.84 times.

A：The company has increased its full-year adjusted EPS guidance to a range of $7.30 to $7.50, an increase of 30 cents from the previous guidance. The company now expects full-year total revenues to be at least $405 billion. The outlook for full-year cash flow from operations has been updated to at least $9.5 billion. The company expects full-year adjusted operating income in the healthcare benefits segment to be in a range of approximately $4.34 billion and full year adjusted operating income in the health services segment to be at least $6.18 billion. Full-year enterprise adjusted operating income is now expected to be in the range of $15.53 to $15.87 billion.

A：Aetna's Q1 performance was positively affected by favorable prior-year developments, particularly in the government business. The company experienced outperformance in non-medical cost items such as net investment income and fees. Despite being early in the year, the company is not yet confident in its ability to deliver the full year's performance.

A：Aetna's commercial business showed strong performance, driven by disciplined pricing, better retention, and new wins. The Medicare and Medicaid businesses also performed well, and the company has been successful in rate advocacy, with rates aligning with acuity. Aetna is focused on returning the business to target margins and enhancing capabilities beyond transaction orientation towards consumer solutions.

A：The indicators of a strong start to the year for Aetna include year-over-year performance improvements across all lines of business, with particularly strong results in government business. The company has also been successful in commercial business, evidenced by growth and disciplined pricing.

A：Aetna is making significant investments in technology, with a vision to transform from a consumer-based healthcare company to a consumer-based healthcare technology company. This shift is driven by a focus on leveraging technology to engage consumers and improve the consumer experience. Investments include AI, consumer solutions, and digital tools to empower members to make better healthcare decisions, which is expected to improve health outcomes and lower costs.

A：Aetna is approaching the deployment of AI through three main areas: investment in AI and broader technology for an improved cost structure and business fundamentals; improving operational processes to enable colleagues to focus on critical tasks; and enhancing member experiences with better insights, navigation, and tools for informed choices.

A：The company views technology as critical to operating in the healthcare industry, aiming to be leading in this aspect. Their strategic approach includes leveraging technology to improve engagement in the healthcare ecosystem, with a focus on better results, outcomes, and cost efficiency for clients. The 'Health 100' initiative is a key part of this strategy, aimed at consumers, to drive better involvement in the healthcare system.

A：Customers expressed surprise and appreciation for the company's efforts to connect various healthcare stakeholders and simplify consumer engagement, which aligns with what the customers have been seeking.

A：The company is navigating changes at both federal and state levels, which include PBM legislation and potential changes to state laws similar to Arkansas. They have been preparing for these changes and the transition to net cost economics for the last two years. They are reinforcing their current path, and new rules are expected to provide durable reimbursement relief for independent pharmacies.

A：The changes are seen as providing durable reimbursement relief to independent pharmacies, which have faced challenges, particularly in certain states.

A：The company is focused on driving costs down and improving the experience for members, as well as providing more predictability and assurances to clients regarding budgeting over the long run.

A：The company is evaluating its options, which include potential legal action, and is engaging in active dialogue with Tennessee officials. They acknowledge the challenges the legislation could pose, such as increased costs for the state and threats to pharmacy access, particularly in certain regions.

A：The company plays a critical role in the pharmacy supply chain by creating competition and driving down costs for medications. They aim to address the affordability challenge by leveraging biosimilars and generics to create value for their customers.

A：The company remains confident in its ability to deliver mid-teens EPS CAGR through 2024 as stated at the investor day back in December. They have scale, diversification, and execution strategies in place to absorb the impact of the new challenges and continue delivering on their commitments.

A：Oak Street performed better in the quarter, and the impact of this performance on the remainder of the year is discussed but not fully detailed in the provided transcript excerpt.

A：The core outperformances mentioned are not fully detailed in the provided transcript excerpt, but they are significant in terms of the company's overall performance and financial results.

A：The company is focusing on differentiating patient care, ensuring the right membership, and maintaining disciplined growth. They are ensuring the adoption of value-based models is on track, working with payers to have appropriate contracts in place, and continuing to optimize the clinical-led model.

A：The flu season has performed in line with expectations, with no significant issues to report. There has been strong medical management and proactive efforts that align with these expectations.

A：The company is focused on retaining share in the GLP-1 market and is managing the cost through formulary competition and robust weight management solutions. The migration to the cost plus model has neutralized the previously negative impact on the business, and margins have improved due to reduced drug prices. The cost manager model benefits both payers and the company, allowing the former to enjoy leading costs on every script while earning a fair margin.

A：The company serves members with GLP-1 medications by leveraging 9,000 local community pharmacies and two markets: the insured market with access and coverage, and the DCC market for lifestyle medications where patients seek alternatives. They ensure that members have access to the full range of benefits through workflows that drive down prices.

A：On the PBM side, the company's strategies include focusing on retail access while benefiting from the net cost model that provides competitive prices compared to the cash marketplace. This model ensures that consumers receive cost-effective solutions without having to choose between their options.

A：The company's commercial businesses, including group risk, are performing well with disciplined pricing and growth across all parts of the business. Medical cost trends are favorable, and enrollment and sales tracking are positive, along with early insights into the performance of commercial fee-based large groups for the upcoming 2027 plan year.

A：The company is investing in innovative solutions that include better navigation, advocacy, and provider care partnerships to enhance the member experience and drive results. These strategies are aimed at becoming an absolute leader in healthcare and are expected to reduce friction and create a more seamless experience for members.